ClinicalTrials.gg
RecruitingNCT06470698TEMPTATIONUpdated Jun 24, 2024

EMA for Predicting Treatment Outcomes in Patients With SUD

An observational study in Substance Use Disorders and Substance Use, sponsored by University of Huelva. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-24.

Sponsored by University of Huelva · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
130
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Substance-Related Disorders with a site in Spain — 6 open to participants now, 7 under way, none of them phase 3. Substance-Related Disorders · Spain.

Started
2023
with 2 others
Observational
6 of 26
2 open now
Registered
21st of 26
by date

Among the 26 studies in Substance-Related Disorders with a site in Spain, this one is one of 3 that started in 2023, is one of 6 observational ones, and was the 21st registered.

Substance-Related Disorders

2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

6 of the 26 studies in Substance-Related Disorders with a site in Spain are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Substance-Related Disorders with a site in Spain, or all of them as a file.
02

Study summary

This longitudinal repeated measures study will evaluate participants at the beginning of treatment through an assessment of psychological measures and craving. They will be trained to use a mobile platform, which will be available for 12 days. The assessment will be conducted via Ecological Momentary Assessment (EMA), with scheduled daily access and during situations of consumption risk. Each access will include questions on substance use, depression, anxiety, triggering situations, attitude towards drugs, and a cognitive bias test. The platform will alternate between two tests (Drug Stroop Task and WAT-DUD). Participants will follow a treatment program supervised by professionals.

The study aims to recruit 130 participants (65 for alcohol, 65 for cocaine) from the Provincial Service for Drug Dependence and Addictions in Huelva (SPDA). Participants, selected via stratified random sampling, must reside in Huelva, sign informed consent, have a compatible mobile device, and be over 18. Anonymity will be ensured through alphanumeric codes.

Upon treatment admission, selected patients will be informed of their participation in the study. Interviews, conducted by psychologists, will outline the study objectives and duration. Patients agreeing to participate will sign informed consent and receive an identification code. Baseline assessment data will be integrated into a database for subsequent statistical analysis. The assessment encompasses the collection of four blocks of information:

Block 1. Patients medical history initiated during treatment admission. Block 2. Neuropsychological battery developed by the research team for the baseline evaluation.

Block 3. Neuropsychological battery developed by the research team for the web platform measured through Ecological Momentary Assessment (EMA).

Block 4. Follow-up information at three and six months provided by SPDA professionals through the patients medical history.

To ensure compliance with participant follow-up, a mixed monitoring protocol has been developed, which includes phone calls and WhatsApp messages. This protocol is designed according to social exchange theory so that participants perceive the benefits of their participation as outweighing the costs.

The statistical analysis involves identifying outliers and trimming distributions. Data will be averaged per test per person, considering different conditions. Repeated measures ANOVA will analyze factors such as gender and substance type to address study objectives, examining interactions and conducting planned contrasts for specific comparisons.

Read the detailed description
  1. Study design: Longitudinal study of repeated measures in which: 1) Participants will undergo a baseline assessment at the beginning of treatment, which will include psychological measures and craving assessment. During this session, they will be logged into a platform via their mobile devices and trained in its use. The platform will be available from this moment onwards and for the next 12 days. 2) At this point, the assessment begins through ecological momentary assessment (EMA). Participants will be required to access the platform once daily during a pre-set time window (Daily Assessment; DA). Participants will also be instructed to access the platform when they experience they are at risk of consuming or acquiring substances (Temptation Assessment; TA). Each access to the platform, whether DA or TA, will include questions assessing substance use, depression, subjective anxiety, triggering situations, attitude toward drugs, and a cognitive bias test. The application will be programmed to administer one of two cognitive bias tests (Drug Stroop Task and WAT-DUD) in an alternate sequence for each participant, so that each test is administered 6 times to each subject (complete within-subjects counterbalancing). Throughout the entire study and during the subsequent months, participants will engage in a substance use treatment program, and clinical professionals from the Provincial Centers for Drug Dependence and Addictions will monitor patients to prevent and/or treat potential relapses.
  2. Participants: The study targets to recruit 130 participants (65 for alcohol, 65 for cocaine) who are receiving treatment for substance use disorder at the Provincial Service for Drug Dependence and Addictions in the province of Huelva (SPDA). The sample will be selected through stratified random sampling with simple allocation based on the primary drug of consumption and gender. To anonymize participant information, the application will not collect personal data. Participants will be assigned an alphanumeric code for identification.
  3. Procedures: At the time of admission to treatment, professionals at addiction treatment centers will inform randomly selected patients that they have been chosen to participate in this study. If they agree to participate, the interview will commence in a designated room at these centers where the psychologist administering the tests will be present. At the outset of the interview, participants will be briefed on the project objectives, duration, and its independent nature from their treatment process, and will be asked if they are interested in participating. In the event that the patient agrees, they will be asked to sign the informed consent form. Additionally, they will be assigned a code that will only allow their identification by the research team personnel, in order to incorporate the gathered information into follow-up assessments. Upon completion of the baseline assessment tests, all data will be integrated with psychological and neuropsychological tests into a database for subsequent statistical analysis. This database will not contain any information enabling patient identification by individuals not involved in the research.

The assessment encompasses the collection of four blocks of information:

Block 1. Patients medical history initiated during treatment admission. The following information will be gathered:

a) Consumption pattern during the 30 days prior to treatment initiation b) Sociodemographic information collected by center professionals.

Block 2. Neuropsychological battery developed by the research team for the baseline evaluation. The estimated time is 90 minutes, including training in the use of the platform. The following tests will be used:

Questionnaire developed by the research team including sociodemographic information and gender-related variables.

State/Trait Depression Inventory (IDER). Craving: Multidimensional Alcohol Craving Scale (EMCA). Cocaine Craving Questionnaire-Now (CCQ-N-10).

Monetary Choice Questionnaire (MCQ). Iowa Gambling Task (IGT). Balloon Analogue Risk Task (BART). Impulsive Behavior Scale (UPPS-P). Anxiety Sensitivity Index (ASI-3). Positive and Negative Affect Schedule (PANAS). Acceptance and Action Questionnaire-II (AAQ-II). Padua Inventory.

Block 3. Neuropsychological battery developed by the research team for the web platform measured through Ecological Momentary Assessment (EMA). The following tests will be utilized:

  1. Cognitive bias assessment: Each access to the platform (DA or TA) will include one of these two tests in an alternate sequence for each participant.

    Drug Stroop Task for mobile devices. Word Association Task for Drug Use Disorder (WAT-DUD)

  2. State/Trait Depression Inventory (IDER). This test is administered on DA on days 2, 6, and 10, and on each TA. Since the complete test is already administered during the baseline assessment, participants will only need to respond to questions related to the State (degree of affectation) during the EMA assessment.
  3. Craving assessment: The test are administered on days 1, 4, 8, and 12, and on each TA.

    Multidimensional Alcohol Craving Scale (EMCA). Cocaine Craving Questionnaire-Now (CCQ-N-10).

  4. In order to obtain relevant information during the EMA follow-up, a series of additional questions are included. These questions address the following:

Subjective anxiety. This question is included at the end of the IDER items. Attitude towards the drug. These questions are integrated into the craving questionnaires (EMCA/CCQ-N-10).

Triggering situation: These questions are integrated into the craving questionnaires (EMCA/CCQ-N-10).

Consumption during follow-up: These questions are presented independently from the rest of the tests before completing each access to the platform.

Before concluding the last two blocks related to the developed neuropsychological battery, it is worth noting that a series of control questions have been included to ensure greater reliability in participants responses. These questions have been included in both the baseline assessment tests and those presented during the EMA follow-up.

Block 4. Follow-up information at three and six months provided by SPDA professionals through the patients medical history: current situation, adherence level, level of involvement according to professional assessment, current substance use and relapses.

To ensure compliance with participant follow-up, a mixed monitoring protocol has been developed, which includes phone calls and WhatsApp messages. This protocol is designed according to social exchange theory so that participants perceive the benefits of their participation as outweighing the costs. Once SPDA professionals provide participant contact information and obtain consent for contact, an initial contact will be made via WhatsApp to schedule a baseline assessment appointment. If there is no response, a phone call will be made. When participants complete the baseline assessment, they will be taught how to use the platform, and the time window for data collection will be established. Participants will receive a welcome and motivation or pre-notification message, which includes elements of personalization and trust, tangible and intangible benefits of study participation, and cost minimization. At the designated time, a notification message will be sent, reminding participants of access hours and providing a direct link to the platform to minimize response costs. If participants do not access the platform daily during the established time window, a reminder message will be sent, even if they are no longer within the mentioned temporal window. This reminder will emphasize the benefits of study participation and provide a link to minimize response costs. If, despite reminders, participants do not access the platform for two consecutive days, a phone call will be made to encourage active participation. After completing the follow-up, a final thank-you message will be sent to participants, informing them of the amount of gift cards they will receive. They will also be reminded that their participation will help others and improve future interventions.

Statistical analysis. First, an analysis will be conducted to identify outliers in the individual responses to the items of each execution of each PSC. Distributions with outliers will be handled by trimming to the 90th percentile, transforming the considered outliers to the equivalent of the 5th and 95th percentiles of the distribution. Subsequently, the average value will be calculated for each test per person based on other variables (distinguishing between daily tests and impulse tests, as well as tests conducted on days of substance consumption versus days of non-consumption). This way, each participant will have an estimated value in the performance of each test under different access conditions (daily and impulse) and under the circumstances of substance consumption or non-consumption. To address the study objectives, data will be analyzed using a repeated measures ANOVA model. This model will have three factors forming different groups of participants (gender, primary substance, and type of admission) and two factors of repeated measures (type of measurement - impulse or daily - and substance consumption on the day of measurement). The full factorial model will be initially analyzed, which examines all main effects and all interactions. If any of the interactions are statistically significant, the results will be analyzed through decomposition into simple effects, as well as the estimation of the magnitude of the interaction. Comparisons for specific objectives will be conducted through planned contrasts.

03

Conditions studied

  • Substance Use Disorders
  • Substance Use

Keywords

  • Ecological Momentary Assessment
  • Substance Use Disorder
  • Cocaine
  • Alcohol
  • Treatment
  • Gender
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Individuals receiving treatment for Substance Use Disorder (SUD) at the Provincial Service for Drug Dependence and Addictions (SPDA) in the province of Huelva, Spain.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients initiating treatment for addiction to cocaine or alcohol as the primary substance.
  2. Patients with a diagnosis of Substance Use Disorder of mild, moderate, or severe severity, according to the 5th Edition of the DSM ().
  3. Maintaining residency in the province of Huelva during the study\'s follow-up period.
  4. Willingness to participate in the study by providing .
  5. Possessing a mobile device that meets the necessary technical requirements for the installation and operation of the application.

Exclusion criteria

Exclusion Criteria:

  1. Patients with severe, unstable mental disorders, as assessed by the clinical team at the treatment centers.
  2. Patients with physical or mental disorders that hinder the execution of the tests and assessments included in the study.
  3. Patients under the age of 18.
  4. Patients with opioid consumption.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
130 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Differences between daily access scores and temptation access scores

    We may find statistically significant differences between the scores obtained during episodes of temptation to consume or purchase substances and those obtained from daily measures, with higher scores during temptation episodes. These differences will be observed in both groups, among both men and women.

    Time frame: Through study completion, an average of 2 years

  2. Relationship between number of episodes of temptations and scores in the tests

    It may be that during the monitoring, those participants who experience a higher number of episodes of temptation will have elevated levels in the scheduled measures. Those participants who have higher scores during episodes of temptation will have a greater number of episodes of consumption. These relationships will be observed in both groups, among both men and women.

    Time frame: Through study completion, an average of 2 years

  3. Differences based on the type of substance

    There may be statistically significant differences in the test scores based on the type of substance.

    Time frame: Through study completion, an average of 2 years

  4. Relationship between the studied variables and variables associated with gender.

    We may find differences in test scores based on gender-related variables.

    Time frame: Through study completion, an average of 2 years

07

Study locations

1 of 1 sites recruiting
  • University of Huelva
    Huelva, 21007, Spain
    Recruiting
    • Ana Segura-Barriga, Psichology · Contactana.segura@dpces.uhu.es · 800-555-5555
    • Enrique Moraleda-Barreno, PhD · Principal investigator
    • José A. Lorca-Marín, PhD · Principal investigator
    • Ana Segura-Barriga, Graduate · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Aug 2025, 25 months after the start.

Of 123 non-industry observational studies under Substance-Related Disorders, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 60. This study's planned 25 months is below that.

Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 18 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2024
First posted
Jun 24, 2024
StartActual
Jul 21, 2023
Primary completionEst.
Aug 2025
CompletionEst.
Aug 2025
Last update
Jun 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06470698
Lead sponsor
University of Huelva
Collaborators
Ministerio de Economía y Competitividad, Spain, State Research Agency, Spain
Responsible party
Enrique Moraleda Barreno (Principal Investigator, University of Huelva) — Principal investigator
First posted
Jun 24, 2024
Start date
Jul 21, 2023
Primary completion
Aug 2025 (estimated)
Completion
Aug 2025 (estimated)
Last update
Jun 24, 2024

Study contacts

Ana Segura-Barriga, Graduate
Contact
ana.segura@dpces.uhu.es
+34 682 78 15 22
Enrique Moraleda-Barreno, PhD
principal investigator · University of Huelva
José A. Lorca-Marín, PhD
principal investigator · University of Huelva
Ana Segura-Barriga, Graduate
principal investigator · University of Huelva

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion